210 related articles for article (PubMed ID: 33139767)
1. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.
Bayik D; Lauko AJ; Roversi GA; Serbinowski E; Acevedo-Moreno LA; Lanigan C; Orujov M; Lo A; Alban TJ; Kim A; Silver DJ; Nagy LE; Brown JM; Allende DS; Aucejo FN; Lathia JD
Sci Rep; 2020 Nov; 10(1):18848. PubMed ID: 33139767
[TBL] [Abstract][Full Text] [Related]
2. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.
Ma C; Zhang Q; Greten TF
Cell Immunol; 2021 Mar; 361():104295. PubMed ID: 33508529
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
[TBL] [Abstract][Full Text] [Related]
4. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
Kalathil SG; Thanavala Y
Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
[TBL] [Abstract][Full Text] [Related]
5. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
6. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
7. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients.
Elwan N; Salem ML; Kobtan A; El-Kalla F; Mansour L; Yousef M; Al-Sabbagh A; Zidan AA; Abd-Elsalam S
Immunol Invest; 2018 Feb; 47(2):169-180. PubMed ID: 29182438
[TBL] [Abstract][Full Text] [Related]
8. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
[TBL] [Abstract][Full Text] [Related]
9. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
10. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
Wang D; An G; Xie S; Yao Y; Feng G
Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
[TBL] [Abstract][Full Text] [Related]
11. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
12. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
14. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum stress induced LOX-1
Nan J; Xing YF; Hu B; Tang JX; Dong HM; He YM; Ruan DY; Ye QJ; Cai JR; Ma XK; Chen J; Cai XR; Lin ZX; Wu XY; Li X
Immunology; 2018 May; 154(1):144-155. PubMed ID: 29211299
[TBL] [Abstract][Full Text] [Related]
16. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
[TBL] [Abstract][Full Text] [Related]
17. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
[TBL] [Abstract][Full Text] [Related]
18. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
Parks AL; McWhirter RM; Evason K; Kelley RK
J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
[No Abstract] [Full Text] [Related]
19. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]